Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec Acquires Cell Culture Service GmbH

Published: Monday, January 07, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Acquisition strengthens cell-based screening and reagent platform at Evotec’s Hamburg site.

Evotec AG has announced the acquisition of all shares in Cell Culture Service GmbH (CCS). CCS is one of the leading suppliers of custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes, and proteins for high throughput screening with more than ten years experience in bulk cell production.

Strengthening Evotec’s position as quality leader in drug discovery solutions

The acquisition of CCS confirms Evotec’s leading position as a fully integrated drug discovery and early development partner for Pharma and biotechnology companies. Integration of CCS’ unique capabilities, such as frozen cell preparations and bulk cell transfection for cell-based screening will enable Evotec’s partners to access the latest science and the best-in-class technology infrastructure to increase efficiency in the drug discovery process.

CCS’ large scale processes for cell production, freezing and storage including the entire team of specialised cell culture scientists and technicians will be fully integrated into Evotec’s Hamburg operations to realise cost synergies and efficiency improvements.

“Through the acquisition of CCS, Evotec strengthens its cell culture capabilities and gains access to a growing base of customers using cell- based assays in their drug discovery processes. CCS’ experience and technologies for large scale cell production are a perfect fit with Evotec’s screening and in vitro pharmacology activities”, said Dr Mario Polywka, Chief Operating Officer of Evotec AG.

Dr Oliver Wehmeier, CEO of CCS, adds: “We are excited to join forces with Evotec. Our portfolio of custom products perfectly complements Evotec’s integrated service offering. In return, our customers, who have relied on CCS’ products and services for many years, will gain access to Evotec's broad range of screening technologies, which add a tremendous value to the assay-ready cells and cell-based reagents we provide.”

Transaction structure reflects value potential

The purchase price consists of a cash consideration of €1.15 m and an earn-out component targeting €1.05 m in cash. The earn-out component will become due following one year after the acquisition and depends upon the achievement of certain revenue targets.

Despite cash requirements for the transaction and integration of approximately €1.2 m in 2012, Evotec confirms its cash guidance for the full year of more than €60 m.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Inspiring Futuristic Innovation: Brain ‘Organoids’
Scientists create artificial brains, providing an advanced model for studying brain tumour development.
Tissue Damage Is Key for Cell Reprogramming
Researchers have shown tissue damage is important for cells to return to an embryonic state for cell reprogramming.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Using Cancer Cells' Mass to Predict Treatment Response
A device has been developed that can detect changes in cell mass at a minute scale.
Color-Coded Stem Cells
Researchers develop colour-coding tool for tracking live blood stem cells over time.
Human Intestines and Functioning Nerves Engineered
The new technology enables the study of human health and advances the goal of regenerative medicine.
Chemical Snapshots Could Lead to Better Engineered Cartilage
Taking "chemical photographs" of the cartilage between joints and comparing it to engineered versions could lead to better implants, say researchers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!